Small Cell Lung Cancer Clinical Trials 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer
Condition: Small Cell Lung Cancer (SCLC) Interventions: Drug: Tarlatamab; Drug: Lurbinectedin; Drug: Topotecan; Drug: Amrubicin Sponsor: Amgen Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 23, 2023 Category: Research Source Type: clinical trials
